Results 71 to 80 of about 27,891 (313)

Semaglutide as Treatment for Obesity in Adolescents [PDF]

, 2023
Background: Semaglutide was recently approved to treat obesity in adolescents. Main objective: To provide a critical appraisal of semaglutide as anti-obesity agent in adolescents. Methods: Pubmed search up to May 19, 2023.
Mikhail, Nasser, Wali, Soma
core   +2 more sources

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Potentiation of the restorative effect of semaglutide on metabolic and hormonal parameters in rats with diet-induced type 2 diabetes mellitus with intranasally administered insulin

Сибирский научный медицинский журнал
Semaglutide, a glucagon-like peptide-1 receptor agonist, is widely used for the treatment of type 2 diabetes mellitus (DM2), but it is not effective in some patients, which requires the development of approaches to enhance its therapeutic effect.
K. V. Derkach, N. E. Basova, A. O. Shpakov   +2 more
doaj   +1 more source

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists [PDF]

, 2014
Patients with type 2 diabetes have a several-fold increased risk of developing cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and stroke are responsible for 75% of all death in patients with diabetes, who present a ...
Andrei C Sposito, Francisco Kerr Saraiva
core   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer, Eliza J. McEwin, Zhicheng Wang, Joel Lexchin, Barbara Mintzes   +4 more
wiley   +1 more source

Gut microbiota mediates semaglutide attenuation of diabetes-associated cognitive decline

Neurotherapeutics
Diabetes-associated cognitive decline (DACD), characterized by cognitive impairment, is a serious complication of diabetes mellitus (DM). Research has shown that semaglutide, a novel glucagon-like peptide-1 receptor agonist, has neurotrophic and ...
Liqin Qi, Huimin Kang, Feihui Zeng, Menglan Zhan, Cuihua Huang, Qintao Huang, Lijing Lin, Guanlian He, Xiaoying Liu, Xiaohong Liu, Libin Liu   +10 more
doaj   +1 more source

Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

The Lancet Gastroenterology and Hepatology, 2023
Summary Background Patients with non-alcoholic steatohepatitis (NASH)-related cirrhosis are at high risk of liver-related and all-cause morbidity and mortality.
R. Loomba, M. Abdelmalek, M. Armstrong, M. Jara, Mette Skalshøi Kjær, N. Krarup, E. Lawitz, V. Ratziu, A. Sanyal, J. Schattenberg, P. Newsome   +10 more
semanticscholar   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source

Impact of semaglutide on osteoarthritis risk in patients with obesity: A retrospective cohort study

Obesity Science & Practice
Background Osteoarthritis (OA) is a prevalent degenerative joint disorder. While the effect of obesity on OA is well documented, less is known about the effect of semaglutide on OA.
Onur Baser, Lauren Isenman, Sefika Baser, Gabriela Samayoa   +3 more
doaj   +1 more source

Glucagon-like peptide-1 and its class B G protein-coupled receptors: A long march to therapeutic successes [PDF]

, 2016
Theglucagon-likepeptide (GLP)-1receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secretedfromthreemajor tissues inhumans,enteroendocrine L cells in the distal intestine, a cells in the ...
Adelhorst, Alastair J. H. Brown, Andersen, Avatapalle, Belin, Brown, Caihong Zhou, Chris de Graaf, Dan Donnelly, Davis, Dehua Yang, Denise Wootten, Denker, Dods, Drucker, Elahi, Ferguson, Gallwitz, Goodman, Green, Grynkiewicz, Gustavson, Göke, Hendrick, Heppner, Hjorth, Holst, Holst, Huang, Jendle, Jesper Lau, Jiayu Liao, Jiejie Deng, Jung-Mo Ahn, La Barre, Laurence J. Miller, Li, Locatelli-Hoops, Lund, Madeleine M. Fletcher, Ming-Wei Wang, Mojsov, Mojsov, Nauck, Nauck, Orskov, Orskov, Patrick M. Sexton, Pocai, Prentki, Rhodes, RICHARD DEQUAN YE, Sancho, Shiue, Steensgaard, Tang-Christensen, Tibaduiza, Tomkin, Unson, Wettergren, Widmann, Wild, Willard, Zunz   +63 more
core   +3 more sources